Derman, B. A., Stefka, A. T., Jiang, K., McIver, A., Kubicki, T., Jasielec, J. K., & Jakubowiak, A. J. (2021). Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer J.

Derman, Benjamin A., Andrew T. Stefka, Ken Jiang, Amanda McIver, Tadeusz Kubicki, Jagoda K. Jasielec, ja Andrzej J. Jakubowiak. "Measurable Residual Disease Assessed By Mass Spectrometry in Peripheral Blood in Multiple Myeloma in a Phase II Trial of Carfilzomib, Lenalidomide, Dexamethasone and Autologous Stem Cell Transplantation." Blood Cancer J 2021.

Derman, Benjamin A., et al. "Measurable Residual Disease Assessed By Mass Spectrometry in Peripheral Blood in Multiple Myeloma in a Phase II Trial of Carfilzomib, Lenalidomide, Dexamethasone and Autologous Stem Cell Transplantation." Blood Cancer J 2021.